{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:22:16Z","timestamp":1792120936421,"version":"4.4.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in patients with newly diagnosed MM. This retrospective study included 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005 and 2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data, with items scored as 0, 0.5, or 1, in which 1 indicated a deficit. The FI was calculated by dividing the total score by the number of nonmissing items. Frailty was defined as FI \u22650.15; 61% were nonfrail, and 39% were frail. Frailty and nonmarried\/relationship status were associated with higher disease stage, decreased the likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. Approximately a quarter of patients had a deterioration in frailty status at 3 to 12\u00a0months, and &amp;lt;10% had improvement. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of patients with newly diagnosed MM. Frailty status is dynamic and should be reassessed during treatment. Social support has prognostic value and should be evaluated in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014624","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T20:10:23Z","timestamp":1734552623000},"page":"1137-1146","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Cumulative deficits frailty index and relationship status predict survival in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dizona","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanika","family":"Kumar","sequence":"additional","affiliation":[{"name":"3Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"LaPlant","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-2590","authenticated-orcid":false,"given":"Terri","family":"Menser","sequence":"additional","affiliation":[{"name":"4Division of Health Care Delivery Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Schaeferle","sequence":"additional","affiliation":[{"name":"4Division of Health Care Delivery Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Aug","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0123","authenticated-orcid":false,"given":"Megan","family":"Weivoda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025032513472287600_bib1","unstructured":"National Cancer Institute; Surveillance, Epidemiology, and End Results Program\n          . Cancer Stat Facts: Myeloma. 2020. Accessed 20 May 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"4","key":"2025032513472287600_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2025032513472287600_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2025032513472287600_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10428194.2018.1509323","article-title":"Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients","volume":"60","author":"Gavriatopoulou","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025032513472287600_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood-2019-121672","article-title":"Undertreatment of older patients with newly-diagnosed multiple myeloma: real world evidence from a Canadian registry cohort","volume":"134","author":"Mian","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032513472287600_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9868","key":"2025032513472287600_bib7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"issue":"suppl 1","key":"2025032513472287600_bib8","first-page":"3146","article-title":"Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87\/Nmsg-18 study group","volume":"130","author":"Stege","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2025032513472287600_bib9","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2025032513472287600_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A\u00a0concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2025032513472287600_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2020.254235","article-title":"Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial","volume":"106","author":"Dold","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2025032513472287600_bib12","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A\u00a0clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025032513472287600_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032513472287600_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A\u00a0simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2025032513472287600_bib15","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2025032513472287600_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jgo.2013.07.010","article-title":"Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different","volume":"5","author":"Broderick","year":"2014","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"8","key":"2025032513472287600_bib17","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cncr.23856","article-title":"Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer","volume":"113","author":"Schnadig","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2025032513472287600_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032513472287600_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A\u00a0standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"issue":"4","key":"2025032513472287600_bib20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2013.07.008","article-title":"Measuring frailty in heart failure: a community perspective","volume":"166","author":"McNallan","year":"2013","journal-title":"Am Heart J"},{"issue":"1","key":"2025032513472287600_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2017.07.126","article-title":"Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer","volume":"147","author":"Kumar","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2025032513472287600_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ygyno.2021.02.027","article-title":"A\u00a0deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy","volume":"161","author":"Mullen","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2025032513472287600_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00043","article-title":"Development of a Medicare health outcomes survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma","volume":"2","author":"Mian","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"31","key":"2025032513472287600_bib24","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","article-title":"Marital status and survival in patients with cancer","volume":"31","author":"Aizer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"37","key":"2025032513472287600_bib25","doi-asserted-by":"crossref","first-page":"62666","DOI":"10.18632\/oncotarget.16989","article-title":"Impact of marital status during diagnosis on cancer-caused specific survival in acute myeloid leukemia patients: a case-control and population-based study","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2025032513472287600_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/16078454.2022.2026027","article-title":"The effect of marital status on the survival of patients with multiple myeloma","volume":"27","author":"Tang","year":"2022","journal-title":"Hematology"},{"issue":"7","key":"2025032513472287600_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clml.2021.02.001","article-title":"The impact of socioeconomic risk factors on the survival outcomes of patients with newly diagnosed multiple myeloma: a cross-analysis of a population-based registry and a tertiary care center","volume":"21","author":"Evans","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025032513472287600_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-022-00648-y","article-title":"Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients","volume":"12","author":"Obeng-Gyasi","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025032513472287600_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bbmt.2016.03.011","article-title":"Association of socioeconomic status with outcomes of autologous hematopoietic cell transplantation for multiple myeloma","volume":"22","author":"Hong","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2025032513472287600_bib30","first-page":"933","article-title":"Development and initial testing of a new socioeconomic status measure based on housing data","volume":"88","author":"Juhn","year":"2011","journal-title":"J\u00a0Urban Health"},{"issue":"5","key":"2025032513472287600_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.24676","article-title":"Hematology patient reported symptom screen to assess quality of life for AL amyloidosis","volume":"92","author":"Warsame","year":"2017","journal-title":"Am J Hematol"},{"issue":"15","key":"2025032513472287600_bib32","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025032513472287600_bib33","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025032513472287600_bib34","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2025032513472287600_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A\u00a0simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025032513472287600_bib36","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025032513472287600_bib37","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/s41375-021-01162-z","article-title":"Improving the identification of frail elderly newly diagnosed multiple myeloma patients","volume":"35","author":"Stege","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2025032513472287600_bib38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"key":"2025032513472287600_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/CCI.19.00094","article-title":"Frailty in older adults with multiple myeloma: a study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"2025032513472287600_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/CIA.S196087","article-title":"Updated perspectives on the management of multiple myeloma in older patients: focus on lenalidomide","volume":"15","author":"Schoenbeck","year":"2020","journal-title":"Clin Interv Aging"},{"issue":"suppl 1","key":"2025032513472287600_bib41","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/blood-2021-148191","article-title":"Lenalidomide dosing and outcomes in transplant-ineligible patients with newly-diagnosed multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"138","author":"Mian","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025032513472287600_bib42","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1002\/cam4.5245","article-title":"Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: results from the Canadian Myeloma Research Group database","volume":"12","author":"Mian","year":"2023","journal-title":"Cancer Med"},{"issue":"8","key":"2025032513472287600_bib43","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2025032513472287600_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-133369","article-title":"Symptom burden in transplant ineligible patients with newly diagnosed multiple myeloma: a population-based study of patient-reported outcomes","volume":"136","author":"Mian","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032513472287600_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood-2021-146862","article-title":"Is symptom burden associated with health care utilization: a longitudinal population-based cohort study of transplant ineligible patients with newly diagnosed multiple myeloma","volume":"138","author":"Mian","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025032513472287600_bib47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/cancers13040590","article-title":"Socioeconomic factors and survival of multiple myeloma patients","volume":"13","author":"Chamoun","year":"2021","journal-title":"Cancers"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1137\/2357607\/blooda_adv-2024-014624-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1137\/2357607\/blooda_adv-2024-014624-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:37:29Z","timestamp":1742942249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1137\/534657\/Cumulative-deficits-frailty-index-and-relationship"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014624","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}